Home / VEGF / Recombinant Human VEGF 165b Protein

Recombinant Human VEGF 165b Protein

Catalog #: 3045-VE
6 Citations Datasheet / COA / SDS
Newer Version Available: BT-VEGF
NEW

Carrier Free

Catalog # Availability Size / Price Qty
3045-VE-025/CF

With Carrier

Catalog # Availability Size / Price Qty
3045-VE-025
R&D Systems Recombinant Proteins and Enzymes
1 Image
Product Details
Citations (6)
FAQs
Supplemental Products
Reviews
Summary Product Datasheets Carrier Free Data Images Reconstitution Calculator Background Related Research Areas

Recombinant Human VEGF 165b Protein Summary

Product Specifications

Purity
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Endotoxin Level
<0.10 EU per 1 μg of the protein by the LAL method.
Activity
Measured by its binding ability in a functional ELISA. Serially diluted Recombinant Human (rh) VEGF165b is added to a Recombinant Human VEGF R2/KDR/Flk‑1 Fc Chimera (Catalog # 357-KD) coated plate (2 μg/mL, 100 μL/well). Bound rhVEGF165b is detected by a human VEGF165b specific antibody (Catalog # MAB3045). The concentration of rhVEGF165b that produces half-maximum response is approximately 0.12-0.6 nM.
Source
Spodoptera frugiperda, Sf 21 (stably transfected)-derived human VEGF protein
Ala27-Asp191
Accession #
AAL27435
N-terminal Sequence
Analysis
Ala27
Structure / Form
Disulfide-linked homodimer
Predicted Molecular Mass
19.1 kDa (monomer)
SDS-PAGE
19-24 kDa, reducing conditions

Product Datasheets

You must select a language.

x

3045-VE (with carrier)

Product Datasheet
COA
SDS

You must select a language.

x

3045-VE/CF (carrier free)

Product Datasheet
COA
SDS

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

3045-VE

Formulation Lyophilized from a 0.2 μm filtered solution in PBS with BSA as a carrier protein.
Reconstitution Reconstitute at 100 μg/mL in PBS containing at least 0.1% human or bovine serum albumin.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

3045-VE/CF

Formulation Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution Reconstitute at 100 μg/mL in PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Background: VEGF

Vascular endothelial growth factor (VEGF or VEGF-A), also known as vascular permeability factor (VPF), is a potent mediator of both angiogenesis and vasculogenesis in the fetus and adult (1-3). It is a member of the PDGF family that is characterized by the presence of eight conserved cysteine residues and a cystine knot structure (4). Humans express two sets of alternately spliced isoforms of 121, 145, 165, 183, 189, and 206 amino acids (aa) in length (4). VEGF165 appears to be the most abundant and potent of the angiogenic isoform set, followed by VEGF121 and VEGF189 (3, 4). The anti-angiogenic or “b” set of isoforms is differentially spliced to contain six alternate amino acids at the C-terminus, and are the more highly expressed isoforms in normal adult tissue (5). VEGF165b, like VEGF121 but unlike most angiogenic isoforms, does not bind heparins and is therefore diffusible (4, 6). Human VEGF165b shares 88% aa sequence identity with corresponding regions of mouse and rat, 96% with porcine, 95% with canine, and 93% with feline, equine and bovine VEGF165b, respectively. VEGFs bind the type I transmembrane receptor tyrosine kinases VEGF R1 (also called Flt-1) and VEGF R2 (Flk-1/KDR) on endothelial cells (4). Although VEGF affinity is highest for binding to VEGF R1, VEGF R2 appears to be the primary mediator of VEGF angiogenic activity (3, 4). The affinity of VEGF165b for VEGF R2 is similar to that of VEGF165, but VEGF165b only partially activates VEGF R2 such that the kinase regulatory site Y1054 is not phosphorylated (6). VEGF165b also does not bind neuropilin-1, suggesting that the functional difference between VEGF165 and VEGF165b maybe due to either the lack of neuropilin-1 co-signaling or unique downstream signaling activated by VEGF165b (8). Since VEGF165b may compete with angiogenic VEGFs for VEGF R2 sites, its ectopic expression in tumors has been shown to inhibit their growth (7).

References
  1. Leung, D.W. et al. (1989) Science 246:1306. 
  2. Keck, P.J. et al. (1989) Science 246:1309. 
  3. Byrne, A.M. et al. (2005) J. Cell. Mol. Med. 9:777. 
  4. Robinson, C.J. and S.E. Stringer (2001) J. Cell. Sci. 114:853.
  5. Nowak, D.G. et al. (2008) J. Cell Sci. 121:3487.
  6. Kawamura, H. et al. (2008) Cancer Res. 68:4683.
  7. Rennel, E.S. et al. (2008) Br. J. Cancer 98:1250.
  8. Harper S.J. and Bates D.O. (2008) Nat. Rev. Cancer 8(11):880.
Long Name
Vascular Endothelial Growth Factor
Entrez Gene IDs
7422 (Human); 22339 (Mouse); 83785 (Rat); 281572 (Bovine); 403802 (Canine); 493845 (Feline); 30682 (Zebrafish)
Alternate Names
MVCD1; VAS; vascular endothelial growth factor A; Vascular permeability factor; Vasculotropin; VEGF; VEGFA; VEGF-A; VEGFMGC70609; VPF; VPFvascular endothelial growth factor

Citations for Recombinant Human VEGF 165b Protein

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

6 Citations: Showing 1 - 6
Filter your results:

Filter by:

  1. CNTF Prevents Development of Outer Retinal Neovascularization Through Upregulation of CxCl10
    Authors: F Bucher, E Aguilar, KV Marra, J Rapp, J Arnold, S Diaz-Aguil, C Lange, H Agostini, G Schlunck, A Stahl, M Friedlande
    Invest. Ophthalmol. Vis. Sci., 2020-08-03;61(10):20.
    Species: Human, Mouse
    Sample Types: Spheroids, Whole Cells
    Applications: Bioassay
  2. VEGF165b, a splice variant of VEGF-A, promotes lung tumor progression and escape from anti-angiogenic therapies through a ?1 integrin/VEGFR autocrine loop
    Authors: A Boudria, C Abou Fayca, T Jia, S Gout, M Keramidas, C Didier, N Lemaître, S Manet, JL Coll, AC Toffart, D Moro-Sibil, C Albiges-Ri, V Josserand, E Faurobert, C Brambilla, E Brambilla, S Gazzeri, B Eymin
    Oncogene, 2018-09-07;0(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  3. Cross-activating c-Met/?1 integrin complex drives metastasis and invasive resistance in cancer
    Authors: A Jahangiri, A Nguyen, A Chandra, MK Sidorov, G Yagnik, J Rick, SW Han, W Chen, PM Flanigan, D Schneidman, S Mascharak, M De Lay, B Imber, CC Park, K Matsumoto, K Lu, G Bergers, A Sali, WA Weiss, MK Aghi
    Proc. Natl. Acad. Sci. U.S.A., 2017-09-26;0(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  4. Inhibition of Single Routes of Intracellular Signaling is Not Sufficient to Neutralize the Biphasic Disturbance of a Retinal Endothelial Cell Barrier Induced by VEGF-A165
    Authors: HL Deissler, GK Lang, GE Lang
    Cell. Physiol. Biochem., 2017-07-18;42(4):1493-1513.
    Species: Bovine
    Sample Types: Whole Cells
    Applications: Bioassay
  5. The control of alternative splicing by SRSF1 in myelinated afferents contributes to the development of neuropathic pain
    Neurobiol Dis, 2016-09-09;96(0):186-200.
    Species: Rat
    Sample Types: In Vivo
    Applications: In Vivo
  6. Detection of VEGF-A(xxx)b isoforms in human tissues.
    Authors: Bates, David O, Mavrou, Athina, Qiu, Yan, Carter, James G, Hamdollah-Zadeh, Maryam, Barratt, Shaney, Gammons, Melissa, Millar, Ann B, Salmon, Andrew H, Oltean, Sebastia, Harper, Steven J
    PLoS ONE, 2013-07-31;8(7):e68399.
    Applications: Western Blot

FAQs

No product specific FAQs exist for this product, however you may

View all Proteins and Enzyme FAQs
Loading...

Reviews for Recombinant Human VEGF 165b Protein

There are currently no reviews for this product. Be the first to review Recombinant Human VEGF 165b Protein and earn rewards!

Have you used Recombinant Human VEGF 165b Protein?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review